drugset / Trial / NCT02581137
Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion
NaSingle-groupOpen-labelPrevention
Summary
This phase IIa trial studies how well metformin hydrochloride works in preventing oral cancer in patients with an oral premalignant lesion (oral leukoplakia or erythroplakia). Oral premalignant lesions look like red or whitish plaques or lesions in the mouth that do not rub off and can be associated with a higher risk of cancer. Metformin hydrochloride may help prevent oral cancer from forming in patients with an oral premalignant lesion.
Timeline
- Start
- 2016-06-10
- Primary completion
- 2017-10-12
- Completion
- 2026-12-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metformin | Small molecule | 2000 mg | Oral |